ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs MXN
16.9508
0.04%
Brent Oil
83.925
0.46%
Bitcoin
58,234.35
-0.01%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Beam Therapeutics Inc (BEAM)

  7. Beam Therapeutics Inc (BEAM) Noticias

BEAM Beam Therapeutics Inc

21.75
0.01 (0.05%)
Pre Mercado
Última actualización: 06:00:06
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Beam Therapeutics Inc BEAM NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.01 0.05% 21.75 06:00:06
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
21.74
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
26/3/202405:30GLOBEBeam Therapeutics Announces Clearance of Clinical Trial..
28/2/202405:30GLOBEBeam Therapeutics to Participate in Upcoming March 2024..
27/2/202406:40EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202406:22EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202405:43EDGAR2Form 8-K - Current report
27/2/202405:30GLOBEBeam Therapeutics Reports Fourth Quarter and Year-End 2023..
05/2/202405:30GLOBEBeam Therapeutics to Participate in the Guggenheim..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202415:47EDGAR2Form 144 - Report of proposed sale of securities
08/1/202405:55EDGAR2Form 8-K - Current report
08/1/202405:30GLOBEBeam Therapeutics Highlights Progress Across Base Editing..
05/1/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202405:30GLOBEBeam Therapeutics to Present at the 42nd Annual J.P. Morgan..
14/12/202315:05EDGAR2Form 8-K - Current report
14/12/202305:30GLOBEBeam Therapeutics Appoints Biotech Executive Christi Shaw to..
20/11/202315:20EDGAR2Form 144 - Report of proposed sale of securities
08/11/202306:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202306:00EDGAR2Form 8-K - Current report
08/11/202305:30GLOBEBeam Therapeutics Reports Pipeline and Business Updates and..
01/11/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202305:59DJNBeam Therapeutics to Sell Rights in Verve Licensing Deal to..
31/10/202305:44EDGAR2Form 8-K - Current report
31/10/202305:00GLOBEBeam Announces Agreement for Lilly to Acquire Beam’s Opt-In..
30/10/202315:41EDGAR2Form 144 - Report of proposed sale of securities
25/10/202305:30GLOBEBeam Therapeutics Presents Preclinical Data Highlighting..
24/10/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/10/202307:50EDGAR2Form 8-K - Current report
19/10/202307:45GLOBEBeam Therapeutics Announces Portfolio Prioritization and..
04/10/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202309:00GLOBEBeam Therapeutics Presents Preclinical Data Highlighting..
05/9/202305:30GLOBEBeam Therapeutics Announces First Patient Dosed in Phase 1/2..
31/8/202305:30GLOBEBeam Therapeutics to Participate in Upcoming September..
09/8/202315:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202306:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202306:11EDGAR2Form 8-K - Current report
08/8/202305:30GLOBEBeam Therapeutics Reports Pipeline Updates and Second..
25/7/202317:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/7/202317:31EDGAR2Form 144 - Report of proposed sale of securities
17/5/202305:30GLOBEBeam Therapeutics to Participate in Upcoming May Investor..
11/5/202305:30GLOBEBeam Therapeutics to Participate in RBC Capital Markets 2023..
10/5/202305:30GLOBEBeam Therapeutics Reports Pipeline Updates and First Quarter..

Su Consulta Reciente

NASDAQ
BEAM
Beam Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados